Charles Schwab Investment Management Inc Aclaris Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.01 - $1.36 $160,214 - $215,734	-158,628 Reduced 37.83%	260,706 $286,000
Q1 2024 May 08, 2024	SELL	$0.92 - $1.44 $15,636 - $24,474	-16,996 Reduced 3.9%	419,334 $519,000
Q4 2023 Feb 06, 2024	SELL	$0.64 - $6.49 $17,218 - $174,606	-26,904 Reduced 5.81%	436,330 $458,000
Q3 2023 Nov 08, 2023	BUY	$6.56 - $10.95 $124,462 - $207,754	18,973 Added 4.27%	463,234 $3.17 Million
Q2 2023 Aug 09, 2023	BUY	$7.89 - $10.64 $268,583 - $362,196	34,041 Added 8.3%	444,261 $4.61 Million
Q1 2023 May 11, 2023	SELL	$7.07 - $17.95 $13,524 - $34,338	-1,913 Reduced 0.46%	410,220 $3.32 Million
Q4 2022 Feb 13, 2023	BUY	$14.33 - $18.37 $137,267 - $175,966	9,579 Added 2.38%	412,133 $6.49 Million
Q3 2022 Nov 14, 2022	BUY	$13.07 - $18.22 $3.24 Million - $4.52 Million	248,235 Added 160.86%	402,554 $6.34 Million
Q2 2022 Aug 15, 2022	BUY	$10.16 - $17.08 $215,910 - $362,967	21,251 Added 15.97%	154,319 $2.16 Million
Q1 2022 May 13, 2022	BUY	$9.74 - $17.92 $40,469 - $74,457	4,155 Added 3.22%	133,068 $2.3 Million
Q4 2021 Feb 11, 2022	BUY	$12.27 - $18.49 $24,503 - $36,924	1,997 Added 1.57%	128,913 $1.88 Million
Q3 2021 Nov 16, 2021	BUY	$13.38 - $18.8 $255,263 - $358,666	19,078 Added 17.69%	126,916 $2.29 Million
Q2 2021 Aug 16, 2021	BUY	$17.08 - $29.6 $1.57 Million - $2.72 Million	92,049 Added 582.99%	107,838 $1.89 Million
Q1 2021 May 17, 2021	SELL	$5.86 - $27.73 $27,635 - $130,774	-4,716 Reduced 23.0%	15,789 $398,000
Q2 2020 Aug 14, 2020	SELL	$1.04 - $1.73 $66,764 - $111,060	-64,197 Reduced 75.79%	20,505 $34,000
Q3 2019 Nov 08, 2019	SELL	$0.79 - $2.47 $96,290 - $301,060	-121,887 Reduced 59.0%	84,702 $92,000
Q2 2019 Aug 09, 2019	BUY	$2.13 - $7.06 $69,776 - $231,278	32,759 Added 18.85%	206,589 $453,000
Q1 2019 May 14, 2019	SELL	$5.63 - $7.84 $146,959 - $204,647	-26,103 Reduced 13.06%	173,830 $1.04 Million
Q4 2018 Feb 14, 2019	BUY	$6.3 - $15.4 $415,006 - $1.01 Million	65,874 Added 49.14%	199,933 $1.48 Million
Q3 2018 Nov 13, 2018	BUY	$14.38 - $20.89 $171,352 - $248,925	11,916 Added 9.76%	134,059 $1.95 Million
Q2 2018 Aug 08, 2018	SELL	$16.46 - $20.33 $56,391 - $69,650	-3,426 Reduced 2.73%	122,143 $2.44 Million
Q1 2018 May 07, 2018	BUY	$17.08 - $25.64 $64,938 - $97,483	3,802 Added 3.12%	125,569 $2.2 Million
Q4 2017 Jan 17, 2018	BUY	$21.47 - $27.8 $628,212 - $813,428	29,260 Added 31.63%	121,767 $3 Million
Q3 2017 Nov 13, 2017	BUY	$23.02 - $28.8 $2.13 Million - $2.66 Million	92,507	92,507 $2.39 Million

Others Institutions Holding ACRS

# of Institutions

Shares Held

50.7M

Call Options Held

30.6K

Put Options Held

Bml Capital Management, LLC Zionsville, IN

14.3M
Shares

$54.2 Million
9.64% of portfolio
Vanguard Group Inc Valley Forge, PA

4.69M
Shares

$17.8 Million
0.0% of portfolio
D. E. Shaw & Co., Inc. New York, NY

3.37M
Shares

$12.8 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.01M
Shares

$11.4 Million
0.0% of portfolio
Rock Springs Capital Management LP Baltimore, MD

2.75M
Shares

$10.5 Million
0.11% of portfolio

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $253M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account